MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561386 | Name: Fasnall
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall also shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with carboplatin.

Chemical Structure

Fasnall
Fasnall
CAS#929978-58-5

Theoretical Analysis

MedKoo Cat#: 561386

Name: Fasnall

CAS#: 929978-58-5

Chemical Formula: C19H22N4S

Exact Mass: 338.1570

Molecular Weight: 338.47

Elemental Analysis: C, 67.42; H, 6.55; N, 16.55; S, 9.47

Price and Availability

Size Price Availability Quantity
10mg USD 300.00 2 Weeks
25mg USD 550.00 2 Weeks
50g USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Fasnall;
IUPAC/Chemical Name
N-(1-Benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine
InChi Key
VSXRMURGJRAOCU-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H22N4S/c1-13-14(2)24-19-17(13)18(20-12-21-19)22-16-8-9-23(11-16)10-15-6-4-3-5-7-15/h3-7,12,16H,8-11H2,1-2H3,(H,20,21,22)
SMILES Code
CC1=C(C)C2=C(NC3CN(CC4=CC=CC=C4)CC3)N=CN=C2S1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Fasnall, a thiophenopyrimidine, is a selective fatty acid synthase (FASN) inhibitor that shows potent anti-tumor activity.
In vitro activity:
Fasnall inhibits growth as it was reported previously for different cell lines at a concentration that we used for SG induction (Figures 4A and 4B). Both HEK293T and HeLa cells exhibited a similar decrease in growth compared with control cells (Figures 4A and S1H). Reference: iScience. 2020 Oct 23; 23(10): 101550. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516299/
In vivo activity:
When given alone, Fasnall reduced tumor volume compared with vehicle-treated animals (day 21, Fasnall treatment volume 436 ± 218 [SD of mean] mm, n = 7, control volume 628 ± 381 mm, n = 9; p = 0.85). Significantly, Fasnall also increased the median survival of the MMTV-Neu mice to 63 days (p = 0.049) compared with animals treated with vehicle alone (Figure 7D). Reference: Cell Chem Biol. 2016 Jun 23; 23(6): 678–688. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443244/
Solvent mg/mL mM
Solubility
Ethanol 25.0 48.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 338.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Amen T, Kaganovich D. Fasnall Induces Atypically Transient Stress Granules Independently of FASN Inhibition. iScience. 2020 Sep 10;23(10):101550. doi: 10.1016/j.isci.2020.101550. PMID: 33083719; PMCID: PMC7516299. 2. Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, Kulkarni MM, Ratcliff AN, Kwiek JJ, Haystead TA. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016 Jun 23;23(6):678-88. doi: 10.1016/j.chembiol.2016.04.011. Epub 2016 Jun 2. PMID: 27265747; PMCID: PMC6443244.
In vitro protocol:
1. Amen T, Kaganovich D. Fasnall Induces Atypically Transient Stress Granules Independently of FASN Inhibition. iScience. 2020 Sep 10;23(10):101550. doi: 10.1016/j.isci.2020.101550. PMID: 33083719; PMCID: PMC7516299. 2. Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, Kulkarni MM, Ratcliff AN, Kwiek JJ, Haystead TA. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016 Jun 23;23(6):678-88. doi: 10.1016/j.chembiol.2016.04.011. Epub 2016 Jun 2. PMID: 27265747; PMCID: PMC6443244.
In vivo protocol:
1. Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, Kulkarni MM, Ratcliff AN, Kwiek JJ, Haystead TA. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016 Jun 23;23(6):678-88. doi: 10.1016/j.chembiol.2016.04.011. Epub 2016 Jun 2. PMID: 27265747; PMCID: PMC6443244.
1: Amen T, Kaganovich D. Fasnall Induces Atypically Transient Stress Granules Independently of FASN Inhibition. iScience. 2020 Sep 10;23(10):101550. doi: 10.1016/j.isci.2020.101550. PMID: 33083719; PMCID: PMC7516299. 2: Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, Kulkarni MM, Ratcliff AN, Kwiek JJ, Haystead TA. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016 Jun 23;23(6):678-88. doi: 10.1016/j.chembiol.2016.04.011. Epub 2016 Jun 2. PMID: 27265747; PMCID: PMC6443244. 3: Micallef P, Wu Y, Bauzá-Thorbrügge M, Chanclón B, Vujičić M, Peris E, Ek CJ, Wernstedt Asterholm I. Adipose Tissue-Breast Cancer Crosstalk Leads to Increased Tumor Lipogenesis Associated with Enhanced Tumor Growth. Int J Mol Sci. 2021 Nov 2;22(21):11881. doi: 10.3390/ijms222111881. PMID: 34769312; PMCID: PMC8585035. 4: Gifford GK, Gifford AJ, Chen Q, Shen Y, Gabrielli S, Gill AJ, Stevenson WS, Best OG. Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma. Leuk Lymphoma. 2020 Aug;61(8):1810-1822. doi: 10.1080/10428194.2020.1742899. Epub 2020 Apr 4. PMID: 32249639. 5: Kulkarni MM, Ratcliff AN, Bhat M, Alwarawrah Y, Hughes P, Arcos J, Loiselle D, Torrelles JB, Funderburg NT, Haystead TA, Kwiek JJ. Cellular fatty acid synthase is required for late stages of HIV-1 replication. Retrovirology. 2017 Sep 29;14(1):45. doi: 10.1186/s12977-017-0368-z. PMID: 28962653; PMCID: PMC5622536. 6: Yang JS, Yoon N, Kong M, Jung BH, Lee H, Park J. USP14 Regulates Cancer Cell Growth in a Fatty Acid Synthase-Independent Manner. Int J Mol Sci. 2021 Dec 14;22(24):13437. doi: 10.3390/ijms222413437. PMID: 34948233; PMCID: PMC8707130. 7: Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L. Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen. Mol Oncol. 2021 Aug;15(8):2026-2045. doi: 10.1002/1878-0261.12951. Epub 2021 May 1. PMID: 33759347; PMCID: PMC8333781. 8: Haystead TAJ. Fluorescent-Linked Enzyme Chemoproteomic Strategy (FLECS) for Identifying HSP70 Inhibitors. Methods Mol Biol. 2018;1709:75-86. doi: 10.1007/978-1-4939-7477-1_6. PMID: 29177652; PMCID: PMC6642669. 9: Oh JE, Jung BH, Park J, Kang S, Lee H. Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics. Cells. 2020 Nov 10;9(11):2447. doi: 10.3390/cells9112447. PMID: 33182594; PMCID: PMC7697567. 10: Elix CC, Salgia MM, Otto-Duessel M, Copeland BT, Yoo C, Lee M, Tew BY, Ann D, Pal SK, Jones JO. Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms. Prostate. 2020 Feb;80(2):162-172. doi: 10.1002/pros.23928. Epub 2019 Nov 26. PMID: 31769890; PMCID: PMC8985763. 11: Grunt TW, Lemberger L, Colomer R, López Rodríguez ML, Wagner R. The Pharmacological or Genetic Blockade of Endogenous De Novo Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells. Front Oncol. 2021 Apr 13;11:610885. doi: 10.3389/fonc.2021.610885. PMID: 33928023; PMCID: PMC8076863.